Video

Dr. Galsky on latest CheckMate-274 data for adjuvant nivolumab in bladder cancer

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Matthew Galsky, MD, discusses the latest data from the phase 3 CheckMate-274 trial. He presented these results at the 2022 AUA Annual Meeting. Based on previously reported CheckMate-274 data, the FDA approved nivolumab (Opdivo) for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement, or PD-L1 status. Galsky, is a professor of Medicine and director of Genitourinary Medical Oncology at the Icahn School of Medicine, Mount Sinai, and the co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute.

      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.